Genomic Risk Modeling Gains Traction as ACC/AHA Guidelines Embrace Polygenic Scores
Event summary
- MyOme demonstrated research validating the integration of polygenic scores and clinical risk factors for coronary artery disease (CAD) prediction.
- The 2026 ACC/AHA dyslipidemia guidelines now recognize high polygenic risk as an ASCVD risk enhancer.
- A study published in the American Journal of Preventive Cardiology evaluated the stability of MyOme’s integrated genetic and clinical risk models.
- MyOme will be presenting at the American College of Cardiology (ACC) Annual Scientific Session in March 2026.
The big picture
The integration of genomics into cardiovascular risk assessment represents a significant shift away from traditional, less precise methods. MyOme’s focus on combining polygenic risk scores with clinical data positions them to capitalize on this trend, but the company’s success hinges on demonstrating clinical utility and navigating evolving regulatory frameworks. The recognition by major medical societies like ACC/AHA validates the approach and creates a tailwind for adoption, but also attracts increased scrutiny and competition.
What we're watching
- Guideline Impact
- The degree to which the ACC/AHA guidelines adoption translates into increased clinical utilization of polygenic risk scores remains to be seen, and will be a key indicator of MyOme's market penetration.
- Model Stability
- Continued validation of the stability and reproducibility of MyOme's integrated models across diverse patient populations will be crucial for widespread clinical acceptance and reimbursement.
- Competitive Landscape
- The emergence of competing genomic risk assessment platforms and the potential for larger diagnostics companies to enter the space could impact MyOme’s market share and pricing power.
Related topics